Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mannitol inhalation - Syntara Limited

Next Previous
X
Search
Drug Profile

Mannitol inhalation - Syntara Limited

Alternative Names: Bronchitol; Mannitol dry powder for inhalation - Syntara Limited

Latest Information Update: 13 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Royal Prince Alfred Hospital
  • Developer Chiesi Farmaceutici; EffRx; Pharmaxis; Syntara Limited
  • Class Anti-inflammatories; Antiallergics; Antibronchitics; Antifibrotics; Mucolytics; Small molecules; Sugar alcohols
  • Mechanism of Action Osmotic diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Bronchiectasis; Cystic fibrosis

Highest Development Phases

  • Marketed Cystic fibrosis
  • Discontinued Allergic rhinitis; Bronchiectasis; Sinusitis

Most Recent Events

  • 04 Dec 2023 Pharmaxis is now called Syntara Limited
  • 29 May 2023 EffRx has been acquired by Abiogen Pharma
  • 15 Feb 2022 Mannitol inhalation licensed to CS Pharmaceuticals in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top